2026 AHA/ACC Acute PE Guidelines

The 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults is a de novo document — not an update, not a revision, but the first comprehensive guideline of its kind. Published in Circulation and JACC on February 19, 2026, it pulls together ten societies and lays out a framework that spans from initial symptom assessment through long-term follow-up.

For those of us managing acute PE in the ICU, this guideline introduces a new severity classification system, sharpens anticoagulation guidance, formalizes the role of PE response teams, and provides a structured approach to advanced therapies and follow-up. If you're a pulmonary and critical care physician, this is your new playbook.

Acute PE affects roughly 470,000 hospitalized patients annually in the U.S., and approximately 1 in 5 high-risk patients die. Despite those numbers, we have been working without a formal AHA/ACC guideline — relying instead on society-specific statements, European guidelines, and institutional protocols that vary wildly between hospitals.

The result has been inconsistency. Different centers risk-stratify differently, escalate therapy at different thresholds, and follow up with different timelines. This guideline is an attempt to unify the approach — recognizing that PE management "is uniquely multidisciplinary and crosses emergency department, inpatient settings, and outpatient clinics."

The writing group, chaired by Mark A. Creager, MD, reviewed the existing evidence base to produce a comprehensive, patient-centered framework. The fact that ten professional societies endorsed this document tells you something about how overdue it was.

Recommendation: Classify patients with acute PE into five clinical categories (A-E) based on symptom severity and risk of adverse outcomes to guide management decisions.

What This Means: This is the headline change. Instead of the traditional "massive, submassive, low-risk" framework we have been using for years, the guideline introduces a more granular system:

This gives us a standardized language to risk-stratify patients across institutions and clinical settings.

Recommendation: In patients with low or intermediate clinical probability of acute PE (<50%), obtain a D-dimer. If elevated, or if clinical probability is high (>50%), proceed directly to imaging. CTPA is the standard diagnostic test.

What This Means: Nothing revolutionary here for most of us, but the guideline formalizes this approach and cements CTPA as the first-line imaging modality. For patients who cannot undergo CTPA (contrast allergy, renal insufficiency), ventilation-perfusion (V/Q) scanning is the recommended alternative.

Recommendation: Direct oral anticoagulants (DOACs) — rivaroxaban, apixaban, edoxaban, or dabigatran — are recommended over vitamin K antagonists for oral anticoagulation. Low-molecular-weight heparin (LMWH) is recommended over unfractionated heparin (UFH) for patients requiring initial parenteral therapy.

What This Means: DOACs win on safety profile, ease of use, and reduced major bleeding risk. This is consistent with where practice has been trending, but the guideline makes it an explicit, first-line recommendation. The exception is pregnancy, where DOACs are not recommended and LMWH remains the standard.

For those of us in the ICU managing sicker PE patients, the preference for LMWH over UFH is worth noting — though the practical reality is that many of our Category D-E patients will still need UFH for its titrability and reversibility in the acute setting.

Recommendation: Patients in Categories D-E may require systemic thrombolysis, catheter-directed thrombolysis, catheter-based mechanical thrombectomy, or surgical embolectomy, depending on clinical severity and available resources.

What This Means: The guideline acknowledges what we already know — that the sickest PE patients need more than anticoagulation alone. What it adds is a structured decision framework tied to the new clinical categories. The guideline also addresses appropriate sedation, ventilation, and mechanical circulatory support for critically ill PE patients, which is directly relevant to our ICU practice.

Recommendation: Multidisciplinary PE response teams — including representatives from vascular medicine, pharmacy, nursing, emergency medicine, cardiac surgery, and the patient/family — are recommended to improve timeliness of care.

What This Means: If your institution has a PERT, this guideline validates it. If your institution does not, this is a strong push to build one. PERTs improve risk stratification, streamline advanced therapy decisions, and improve follow-up — all things that are hard to do well without a coordinated team.

Recommendation: Continuation of anticoagulation beyond the initial 3-6 month treatment phase is recommended in patients with a first acute PE without a major reversible risk factor and/or with a persistent risk factor.

What This Means: This is a meaningful shift toward longer-duration anticoagulation in the unprovoked PE population. The data supports it — recurrence rates are significant in patients taken off anticoagulation after an unprovoked event. The guideline recommends periodic reassessment of risks and benefits at each follow-up.

Recommendation: Follow-up communication or clinic visit within one week of discharge, a clinic visit by three months, and screening for chronic thromboembolic pulmonary disease (CTEPD) at every visit for at least one year.

What This Means: This is where the guideline pushes us beyond the acute phase. CTEPD is underdiagnosed, and many patients with persistent dyspnea after PE never get properly evaluated. The guideline also recommends screening for depression, anxiety, and PTSD — conditions that are common after PE but rarely addressed systematically.

This is not an update to an existing document. This is the first-ever AHA/ACC guideline for acute PE, which means it is starting from scratch rather than iterating on prior recommendations. The key additions:

The elephant in the room is the advanced therapy space. Catheter-directed therapies for PE have exploded in the last several years, but the evidence base is still evolving. The guideline acknowledges this but does not draw hard lines on when to use catheter-directed thrombolysis versus mechanical thrombectomy versus surgical embolectomy — largely because the head-to-head data does not exist yet. The recommendation essentially comes down to clinical judgment and local expertise, which is honest but not always helpful when you are standing at the bedside at 2 AM.

The new A-E classification system also needs real-world validation. It is well-constructed on paper, but whether it actually changes outcomes compared to the existing risk stratification tools (sPESI, PESI, troponin, BNP, RV imaging) remains to be seen. Adding a new system on top of established tools creates a transition period where clinicians are juggling multiple frameworks.

The guideline also acknowledges that implementation depends heavily on local resources. Not every hospital has a PERT. Not every hospital has interventional radiology or cardiac surgery available around the clock. For community hospitals and smaller centers, some of these recommendations will be aspirational rather than immediately actionable.

Acute PE is terrifying — sudden shortness of breath, chest pain, the feeling that something is seriously wrong. For too long, the care patients received depended heavily on which hospital they landed in and which physician was on call. This guideline changes that by creating a standardized classification system that links severity to specific treatment strategies. A patient in Category B should be managed the same way whether they present to an academic medical center or a community hospital.

The follow-up recommendations are equally important. Many PE patients are discharged with a prescription for anticoagulation and little else — no structured follow-up, no screening for CTEPD, no assessment of psychological impact. This guideline establishes clear timelines and expectations for post-acute care, which means fewer patients falling through the cracks.

We finally have a unified playbook. The A-E classification gives us a shared language for risk stratification that works across disciplines — emergency medicine, hospital medicine, pulmonary/critical care, interventional cardiology, vascular surgery. When the PERT gets activated, everyone is working from the same framework.

The anticoagulation guidance is clean and practical. DOACs first, LMWH over UFH for parenteral therapy, and a clear recommendation for extended anticoagulation in unprovoked PE. These are decisions we make daily, and having guideline-level backing simplifies the conversation with patients and colleagues.

Where it gets murkier is the advanced therapy space. For Category D-E patients, the guideline outlines the options — systemic thrombolysis, catheter-based interventions, surgical embolectomy — but leaves the specific choice to clinical judgment and local capability. That is appropriate given the evidence, but it means we still need institutional protocols and experienced teams to navigate those decisions in real time.

PE is a resource-intensive diagnosis. Diagnostic workups, ICU admissions, advanced interventional procedures, extended anticoagulation, and long-term follow-up all carry significant costs. This guideline has the potential to reduce unnecessary spending by clarifying which patients can be safely managed as outpatients (Categories A-B) and which truly need hospitalization and escalation.

The push for PERTs is a structural investment. Building a multidisciplinary PE response team requires coordination, staffing, and institutional buy-in — but the evidence suggests it pays off in better outcomes and more efficient resource utilization. Health systems that invest in this infrastructure will be better positioned to manage the growing volume of PE diagnoses.

The follow-up recommendations also create an opportunity for quality improvement. When every PE patient has a defined follow-up timeline — one week, three months, one year — systems can measure adherence, identify gaps, and track long-term outcomes in ways that were not previously standardized.

Here is what changes for us in the ICU and on the wards:

Read the full guidelines here: 2026 AHA/ACC Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults, Circulation